Physician profile
Jayesh Thakkar
NPI 1780778977
$7,883.99
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,182 · 2020: $2,684 · 2021: $2,830 · 2024: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $976.29 | 2019-2024 | Repatha |
| Pfizer INC. | $797.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $706.45 | 2019-2021 | |
| Abbvie INC. | $523.87 | 2021 | |
| Novo Nordisk INC | $492.84 | 2019-2021 | |
| Lilly USA, LLC | $479.03 | 2019-2021 | |
| Allergan, INC. | $407.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $406.71 | 2019-2021 | |
| Astellas Pharma US INC | $392.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $392.74 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $375.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $349.63 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.20 | 2019-2021 | |
| Eisai INC. | $143.25 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $134.25 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.15 | 2019-2021 | |
| Amarin Pharma, INC. | $129.44 | 2019-2021 | |
| Sanofi Pasteur INC. | $106.11 | 2019-2021 | |
| Biogen, INC. | $103.36 | 2021 | |
| Adlon Therapeutics L.P. | $97.46 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $70.25 | 2019-2020 | |
| Shire North American Group INC | $60.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.88 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $53.66 | 2021 | |
| Currax Pharmaceuticals LLC | $50.87 | 2021 | |
| Genentech USA, INC. | $40.41 | 2020-2021 | |
| Horizon Therapeutics Plc | $31.64 | 2019 | |
| Medicure Pharma INC. | $27.63 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.94 | 2021 | |
| Esperion Therapeutics, INC. | $17.64 | 2020 | |
| Cranial Technologies, INC | $15.40 | 2019 | |
| Phadia US INC. | $14.87 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.